NYU Langone Health sets benchmark for heart attack survival rates

NYU Langone Health has the lowest heart attack mortality rate in the country, according to the latest data from the Centers for Medicare and Medicaid Services (CMS).

The CMS report tracks the number of Medicare patients aged 65 and older who die within 30 days of being hospitalized for various conditions, including heart attack. The data covers deaths from July 2020 to June 2023 and was last updated July 2024. NYU Langone's 30-day mortality rate for heart attack patients across all hospitals in the system is an impressive 7.7 percent, significantly lower than the national benchmark of 13.7 percent.

These outstanding outcomes are a direct result of the seamless, team-based care NYU Langone Heart provides. We continue to expand and enhance our clinical programs, particularly in interventional cardiology, advanced heart failure, and critical care. Whether a patient needs a plan to prevent heart disease, a procedure to open a blocked artery or repair a valve, or even a new heart, our specialists work together to provide the best-possible care."

Sunil Rao, MD, director of the Cardiac Catheterization Laboratory and interventional cardiology at NYU Langone Heart

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New study identifies potential target for treating diabetic cardiomyopathy